Literature DB >> 32918142

Cultural adaptation and validation of the Systemic Sclerosis Quality of Life questionnaire into Arabic language.

Samah M Alian1, Nagwa A Sherby1, Shymaa A Sarhan2.   

Abstract

BACKGROUND AND OBJECTIVES: Systemic sclerosis (SSc) is a chronic connective tissue disease affecting all quality of life (QoL) parameters. In addition to clinical assessment, QoL measures should be included in patient assessment. There is no Arabic tool specific for assessing QoL in Arabic SSc patients; therefore, this work was designed to translate the SScQoL questionnaire, culturally adapt and check its reliability and validity.
METHOD: Based on the principle of translation and cross-cultural adaptation in other language, the SScQoL questionnaire was translated into Arabic. Correlation of SScQoL scores for 50 patients with Short Form Health Survey (SF-36) scores has been tested for convergent validity and discriminate validity evaluated by stratifying clinical parameters of patients and disease subtypes. The intraclass correlation coffee (ICC) was used to assess reliability by interviewing patients twice 14 days apart.
RESULTS: Correlations were present between SScQoL scores and physical and mental component scores of SF-36 questionnaire. We found strong negative correlation between the physical component of SF-36 and QoL function, QoL emotion, QoL total scores (r = - 0.654**, r = - 0.512**, r = - 0.540**) and moderate negative correlation present between SF-36 mental component and QoL function, QoL emotion, QoL social, and QoL total (r = - 0.314*, r = - 0.486**, r = - 0.357*, r = - 0.433*). Also, significant association (P < 0.05*) between scores of total QoL and visceral involvements (GIT involvement, pericardial effusion, and LVDD) was evident. The Arabic edition of SScQoL has a Cronbach's alpha of 0.78.
CONCLUSION: The translated Arabic version is a valid and reliable tool to assess Egyptian SSc patients' QoL. Key Points • The SScQoL questionnaire items have a convergent validity with physical and mental component scores of SF-36, and discriminant validity with visceral involvement. • The Arabic edition of SScQoL is reliable with a Cronbach's alpha of 0.78.

Entities:  

Keywords:  Quality of life; Questionnaire; Systemic sclerosis; Validity

Mesh:

Year:  2020        PMID: 32918142     DOI: 10.1007/s10067-020-05373-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  5 in total

1.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  Validity of the Swedish version of the systemic sclerosis quality of life questionnaire (SSCQoL): A novel measure of quality of life for patients with systemic sclerosis.

Authors:  Gunnel Sandqvist; Roger Hesselstrand
Journal:  Ann Rheum Dis       Date:  2019-01-04       Impact factor: 19.103

3.  Gastrointestinal manifestations on impaired quality of life in systemic sclerosis.

Authors:  Hong Yang; Dong Xu; Meng Tao Li; Yao Yao; Meng Jin; Xiao Feng Zeng; Jia Ming Qian
Journal:  J Dig Dis       Date:  2019-04-02       Impact factor: 2.325

4.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

Authors:  P Clements; P Lachenbruch; J Siebold; B White; S Weiner; R Martin; A Weinstein; M Weisman; M Mayes; D Collier
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

5.  Factors associated with quality of life in systemic sclerosis: a cross-sectional study.

Authors:  Matylda Sierakowska; Halina Doroszkiewicz; Justyna Sierakowska; Marzena Olesińska; Agnieszka Grabowska-Jodkowska; Marek Brzosko; Piotr Leszczyński; Katarzyna Pawlak-Buś; Bogdan Batko; Piotr Wiland; Maria Majdan; Małgorzata Bykowska-Sochacka; Wojciech Romanowski; Aleksandra Zon-Giebel; Sławomir Jeka; Mwidimi Ndosi
Journal:  Qual Life Res       Date:  2019-09-03       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.